Editorial: Ovarian cancer biomarker screening: Still too early to tell

Women's Health

Volumn 6, Issue 4, 2010, Pages 487-490

  Anderson, Garnet L ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4; MESOTHELIN; DIAGNOSTIC AGENT; MEMBRANE PROTEIN; MUC16 PROTEIN, HUMAN;

BLOOD ANALYSIS; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; EDITORIAL; FALSE POSITIVE RESULT; FEMALE; GENE OVEREXPRESSION; GENOMICS; HUMAN; METABOLOMICS; OVARIECTOMY; OVARY CANCER; PREDICTIVE VALUE; PROGNOSIS; PROTEOMICS; SENSITIVITY AND SPECIFICITY; TRANSVAGINAL ECHOGRAPHY; GENETICS; METHODOLOGY; OVARY TUMOR; PATHOLOGY; TIME;

BIOLOGICAL MARKERS; CA-125 ANTIGEN; EARLY DETECTION OF CANCER; FEMALE; GENOMICS; HUMANS; MEMBRANE PROTEINS; OVARIAN NEOPLASMS; PROGNOSIS; PROTEOMICS; TIME FACTORS;

EID: 77954417004     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.10.33     Document Type: Editorial

References (28)

1. Urban N, McIntosh MW, Andersen M, Karlan BY: Ovarian cancer screening. Hematol. Oncol. Clin. North Am. 17(4), 989-1005 (2003). (Pubitemid 37022154)
2. Bast RC Jr, Klug TL, St John E et al.: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med. 309, 883-887 (1983).
3. Jacobs I, Bast RC Jr: The CA125 tumour-associated antigen: a review of the literature. Hum. Reprod. 4, 1-12 (1989). (Pubitemid 19069900)
4. Zurawski VR, Orjaseter H, Andersen A, Jellum E: Elevated serum CA-125 levels priorto diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int. J. Cancer 42, 677-680 (1988). (Pubitemid 19008906)
5. Anderson GL, McIntosh M, Wu L et al.: Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J. Natl Cancer Inst. 102(1), 26-37 (2009).
6. Lu KH, Patterson AP, Wang L et al.: Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin. Cancer Res. 10, 3291-3300 (2004). (Pubitemid 38685433)
7. Jurisicova A, Jurisica I, Kislinger T: Advances in ovarian cancer proteomics: the quest for biomarkers and improved therapeutic interventions. Expert Rev. Proteomics 5(4), 551-560 (2009).
8. Ku C, Kulasingam V, Gunawardana CG et al.: Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers. Mol. Cell. Proteomics 8(4), 661-669 (2009).
9. Anderson NL: The roles of multiple proteomic platforms in a pipeline for new diagnostics. Mol. Cell. Proteomics 4, 1441-1444 (2005).
10. Odunsi K: Cancer diagnostics using 1H-NMR-based metabonomics. Ernst Schering Found. Symp. Proc. (4), 205-226 (2007).
11. Nosov V, Su F, Amneus M et al.: Validation of serum biomarkers for detection of early stage ovarian cancer. Am. J. Obstet. Gynecol. 200(6), 639.E1-639.E5 (2009). (Pubitemid 41739936)
12. Bertenshaw GP, Yip P, Seshaiah P et al.: Multianalyte profling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 17(10), 2872-2881 (2008).
13. Havrilesky LJ, Whitehead CM, Rubatt JM et al.: Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol. Oncol. 110(3), 374 (2008).
14. Visintin I, Feng Z, Longton G et al.: Diagnostic markers for early detection of ovarian cancer. Clin. Cancer Res. 14(4), 351-356 (2008). (Pubitemid 351302552)
15. Thorpe JD, Duan X, Forrest R et al.: Effects of blood collection conditions on ovarian cancer serum markers. PLoS One 2(12), E1281 (2007). (Pubitemid 351722471)
16. Drapkin R, von Horsten HH, Lin Y et al.: Human epidiymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian cancinomas. Cancer Res. 65(6), 2162-2169 (2005). (Pubitemid 40490123)
17. Nolen B, Velikokhatnaya L, Marrangoni A et al.: Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol. Oncol. 117(3), 440-445 (2010).
18. Palmer C, Duan X, Hawley S et al.: Systematic evaluation of candidate blood markers for detecting ovarian cancer. PLoS One 3(7), E2633 (2008).
19. Ghosh D, Yuan Z: Combining multiple biomarker models in logistic regression. Biometrics 64(2), 431-439 (2008). (Pubitemid 351698860)
20. Brown PO, Palmer C: The preclinical natural history of serous ovarian cancer: defning the target for early detection. PLOS Med. 6(7), E10000114 (2009).
21. Etzioni R, Kooperberg C, Pepe M, Smith R, Gann PH: Combining biomarkers to detect disease with application to prostate cancer. Biostatistics 4, 523-538 (2003).
22. Pfeiffer RM, Bur E: A model-free approach to combining biomarkers. Biom J. 50(4), 558-570 (2008).
23. Tan TZ, Quek C, Ng GS, Razvi K: Ovarian cancer diagnosis with complementary learning fuzzy neural network. Artif. Intell. Med. 43(3), 207-222 (2008).
24. Skates SJ, Menon U, MacDonald N et al.: Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J. Clin. Oncol. 21(Suppl.), 206S-210S (2003).
25. McIntosh MW, Urban N: A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarker. Biostatistics 4, 27-40 (2003). (Pubitemid 36116886)
26. Kobayashi H, Yamada Y, Sado T et al.: A randomized study of screening for ovarian cancer: a multicenter study in Japan. Int. J. Gynecol. Cancer 18, 414-420 (2008). (Pubitemid 351668303)
27. Partridge E, Kreimer AR, Greenlee RT et al.: Results from four rounds of ovarian cancer screening in a randomized trial. Obstet. Gynecol. 113, 775-782 (2009).
28. Menon U, Gentry-Maharaj A, Hallett R et al.: Sensitivity and specifcity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers; results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 10(4), 327-340 (2009).